Gilead Sciences management check
GILD · Health Care · Biotechnology · CEO Daniel Patrick O'Day
Filings as of
6 good · 1 to watch · 0 flagged, across the seven questions below.
- Good
Have owners done well?
Beat its chosen peers$100 invested at the start of fiscal 2021 grew to $255, against $125 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.69 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good
What does the CEO cost owners?
0.3% of net income$28.4m of reported pay in fiscal 2025, against $8.5bn of net income.
- Watch
Do they own the stock?
CEO stake ≈ 3.0 years of payThe CEO holds 569,683 shares, directly or through trusts (unvested awards not counted): about 3.0 years of pay. Light activity: no buys, $26.6m sold in six months. 44 of 44 sales ran on pre-arranged 10b5-1 plans.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -0.1% a year over the last three fiscal years. Stock-based pay was 3.0% of revenue in the latest year.
- Good
Is leadership stable?
7 leadership filings in 3 yearsCEO in the pay table: Mr. O’Day. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 100 | 26 | |
| Pay for performance | 85 | 85 | |
| CEO cost | 90 | 44 | |
| Skin in the game | 59 | 46 | |
| Dilution | 51 | 68 | |
| Stable leadership | 90 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Biotechnology, by management score. Gilead Sciences is 4th of 60 in its sector.
- 19VRTXVertex Pharmaceuticals86
- 43GILDGilead Sciences82
- 93REGNRegeneron Pharmaceuticals77
- 136AMGNAmgen73
- 199ABBVAbbVie69
- 298INCYIncyte61
- 401MRNAModerna53
- 447BIIBBiogen47
Pay versus performance
From the proxy statement filed March 20, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. O’Day | $28.4m | $63.3m | $9.2m | $255 | $125 | $8.5bn |
| 2024 | Mr. O’Day | $23.7m | $44.8m | $7.7m | $187 | $93 | $480.0m |
| 2023 | Mr. O’Day | $22.6m | $15.5m | $7.6m | $157 | $94 | $5.6bn |
| 2022 | Mr. O’Day | $21.6m | $55.0m | $7.9m | $161 | $90 | $4.6bn |
| 2021 | Mr. O’Day | $19.2m | $31.5m | $6.3m | $130 | $100 | $6.2bn |
The board says pay is tied most to Net Product Sales. Its other key measures: Relative TSR, Adjusted Operating Income.
Insiders and the CEO's stake
Daniel Patrick O'Day (Chairman & CEO) held 569,683 shares directly after their latest Form 4 on Oct 1, 2026, roughly $84.7m at that filing's price.
Light activity: no buys, $26.6m sold in six months. 44 of 44 sales ran on pre-arranged 10b5-1 plans.
- SoldDaniel Patrick O'DayChairman & CEO · 10b5-1 plan$11.6mOct 1, 2026
- SoldJohanna MercierChief Comm & Corp Aff Officer · 10b5-1 plan$9.2mOct 15, 2026
- SoldAnthony WeltersDirector · 10b5-1 plan$2.7mAug 26, 2026
- SoldAndrew D DickinsonChief Financial Officer · 10b5-1 plan$2.5mOct 15, 2026
Leadership and governance on file
- Nov 19, 2025Leadership change8-K 5.02
- Aug 14, 2025Leadership change8-K 5.02
- Mar 12, 2025Leadership change8-K 5.02
- Dec 13, 2024Leadership change8-K/A 5.02
- Jul 17, 2024Leadership change8-K 5.02
- Mar 14, 2024Leadership change8-K 5.02
- Feb 2, 2024Leadership change8-K 5.02
- May 5, 2023Leadership change8-K 5.02
- Jul 28, 2022Leadership change8-K 5.02
- May 31, 2022Leadership change8-K 5.02
- Jan 6, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 4, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $25.1bn returned to owners in buybacks and dividends, 98% of net income, and $3.8bn of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $27.3bn | $27.3bn | $27.1bn | $28.8bn | $29.4bn |
| Net income | $6.2bn | $4.6bn | $5.7bn | $480.0m | $8.5bn |
| Stock-based pay | $635.0m | $637.0m | $766.0m | $835.0m | $894.0m |
| Buybacks | $546.0m | $1.4bn | $1.0bn | $1.1bn | $1.9bn |
| Dividends | $3.6bn | $3.7bn | $3.8bn | $3.9bn | $4.0bn |
| Diluted shares | 1262m | 1262m | 1258m | 1255m | 1255m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.